.Attributes Medicine, Posted online: thirteen September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized phase 3b/4 DESTINY-Breast12 research, trastuzumab deruxtecan (T-DXd) therapy of clients along with HER2+ state-of-the-art breast cancer and also energetic or steady mind metastases presented steady intracranial task and systemic efficiency of T-DXd.